Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

BioDrugs - United Kingdom
doi 10.1007/s40259-016-0184-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

Advances in Therapy
MedicinePharmacology
2019English

Comparative Clinical Efficacy and Safety of the Proposed Biosimilar ABP 710 With Infliximab Reference Product in Patients With Rheumatoid Arthritis

Arthritis Research & Therapy
2020English

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

2018English

Physicochemical and Functional Characterization of a Biosimilar Adalimumab ZRC-3197

Biosimilars
2014English

A Budget Impact Analysis of Adalimumab Biosimilar: The Italian Context

AboutOpen
2019English

Case Study: Biosimilar Anti TNFalpha (Adalimumab) Analysis of Fc Effector Functions

BMC Proceedings
BiochemistryMedicineGeneticsMolecular Biology
2013English

Pharmacokinetic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial

Annals of Hematology
MedicineHematology
2010English

Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis

Clinical Rheumatology
MedicineRheumatology
2019English

Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® With a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology

BioDrugs
MedicineBiotechnologyPharmacology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy